Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase 1 2

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 2Head & Neck 2Gynecologic 2Genitourinary 2Dermatologic 2Lymphoid 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 699Lung Neoplasms 297Small Cell Lung Carcinoma 149Colorectal Neoplasms 113Melanoma 106Neoplasms 93Breast Neoplasms 93Ovarian Neoplasms 92Neoplasm Metastasis 85Squamous Cell Carcinoma of Head and Neck 83Stomach Neoplasms 81Pancreatic Neoplasms 78Carcinoma, Renal Cell 66Triple Negative Breast Neoplasms 63Esophageal Neoplasms 51Endometrial Neoplasms 48Uterine Cervical Neoplasms 47Head and Neck Neoplasms 47Mesothelioma 42Mesothelioma, Malignant 41Sarcoma 40Prostatic Neoplasms 36Urinary Bladder Neoplasms 34Carcinoma, Transitional Cell 32Colonic Neoplasms 31Carcinoma, Hepatocellular 31Adenocarcinoma of Lung 31Carcinoma 26Recurrence 21Thyroid Neoplasms 20

Interventions

pembrolizumab 1epacadostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Microsatellite Instability × Thoracic × Clear all
NCT05592626 2025-07-09

START-001

Marengo Therapeutics, Inc.

Phase 1/2 Recruiting
365 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Abdominal Neoplasms, Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Carcinoma, Basal Cell, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Genital Neoplasms, Female, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Nasopharyngeal Neoplasms, Neoplasms, Neoplasms by Site, Stomach Neoplasms, Urogenital Neoplasms, Vulvar Diseases, Vulvar Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Epstein-Barr Virus Infections, Papillomavirus Infections, Microsatellite Instability, Small Cell Lung Carcinoma

NCT02178722 2022-02-14

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

Incyte Corporation

Phase 1/2 Completed
444 enrolled 19 charts
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Microsatellite Instability, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡